Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Keith Thomas Flaherty, M.D.

Co-Author

This page shows the publications co-authored by Keith Flaherty and Genevieve Boland.
Connection Strength

2.306
  1. Early use of high-dose-glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy. Clin Cancer Res. 2021 Aug 10.
    View in: PubMed
    Score: 0.248
  2. Evolution of delayed resistance to immunotherapy in a melanoma responder. Nat Med. 2021 06; 27(6):985-992.
    View in: PubMed
    Score: 0.244
  3. Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort. J Immunother Cancer. 2021 02; 9(2).
    View in: PubMed
    Score: 0.240
  4. Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome. Sci Adv. 2020 Nov; 6(46).
    View in: PubMed
    Score: 0.236
  5. Neural crest-like stem cell transcriptome analysis identifies LPAR1 in melanoma progression and therapy resistance. Cancer Res. 2021 Aug 30.
    View in: PubMed
    Score: 0.062
  6. Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. Sci Transl Med. 2021 02 17; 13(581).
    View in: PubMed
    Score: 0.060
  7. Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma. Clin Cancer Res. 2020 11 15; 26(22):6039-6050.
    View in: PubMed
    Score: 0.058
  8. Reversal of pre-existing NGFR-driven tumor and immune therapy resistance. Nat Commun. 2020 08 07; 11(1):3946.
    View in: PubMed
    Score: 0.058
  9. Author Correction: PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. Nat Immunol. 2019 Nov; 20(11):1555.
    View in: PubMed
    Score: 0.055
  10. A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors. Clin Cancer Res. 2019 11 15; 25(22):6852-6867.
    View in: PubMed
    Score: 0.054
  11. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. Nat Immunol. 2019 09; 20(9):1231-1243.
    View in: PubMed
    Score: 0.054
  12. Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition. Cancer Immunol Immunother. 2019 Jun; 68(6):897-905.
    View in: PubMed
    Score: 0.053
  13. Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. Mol Syst Biol. 2019 03 11; 15(3):e8323.
    View in: PubMed
    Score: 0.053
  14. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2019 Jan 10; 176(1-2):404.
    View in: PubMed
    Score: 0.052
  15. Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature. 2019 01; 565(7738):E4.
    View in: PubMed
    Score: 0.052
  16. ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma. Cancer Discov. 2019 03; 9(3):396-415.
    View in: PubMed
    Score: 0.052
  17. Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat Med. 2018 Dec; 24(12):1942.
    View in: PubMed
    Score: 0.052
  18. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 2018 11 01; 175(4):984-997.e24.
    View in: PubMed
    Score: 0.051
  19. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2018 11 01; 175(4):998-1013.e20.
    View in: PubMed
    Score: 0.051
  20. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat Med. 2018 10; 24(10):1545-1549.
    View in: PubMed
    Score: 0.051
  21. Toward Minimal Residual Disease-Directed Therapy in Melanoma. Cell. 2018 08 09; 174(4):843-855.e19.
    View in: PubMed
    Score: 0.050
  22. Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO Mol Med. 2018 05; 10(5).
    View in: PubMed
    Score: 0.049
  23. Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Clin Cancer Res. 2018 10 01; 24(19):4771-4784.
    View in: PubMed
    Score: 0.049
  24. Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence. Cell Rep. 2017 Dec 05; 21(10):2796-2812.
    View in: PubMed
    Score: 0.048
  25. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov. 2018 02; 8(2):196-215.
    View in: PubMed
    Score: 0.048
  26. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017 10 26; 8(1):1136.
    View in: PubMed
    Score: 0.048
  27. PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature. 2017 10 05; 550(7674):133-136.
    View in: PubMed
    Score: 0.047
  28. Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response. Cancer Res. 2017 05 01; 77(9):2318-2327.
    View in: PubMed
    Score: 0.046
  29. Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget. 2017 Apr 11; 8(15):25395-25417.
    View in: PubMed
    Score: 0.046
  30. Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. J Clin Invest. 2015 Apr; 125(4):1459-70.
    View in: PubMed
    Score: 0.040
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.